Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma

Abstract

SP-free survival can be regarded as an end-point for TACE refractoriness. Development of progression or need for three sessions of TACE within the first 6 months could be predictive of TACE refractoriness.